Supernus Pharma Stock Price, News & Analysis

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. According to the company’s public disclosures, Supernus has built a diverse neuroscience portfolio with approved treatments that address a range of neurological and psychiatric conditions, and it continues to develop a broad set of product candidates for additional CNS disorders.

The company states that its portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. These products are part of a neuroscience franchise that spans both movement disorders and psychiatric conditions. Supernus describes itself as developing a broad range of novel product candidates for CNS disorders, reflecting an ongoing research and development effort alongside its commercial operations.

Supernus trades on The Nasdaq Stock Market LLC under the ticker symbol SUPN, as confirmed in multiple Form 8-K filings where its common stock, with a par value of $0.001 per share, is listed. The company identifies itself in those filings as Supernus Pharmaceuticals, Inc., and it notes that there is no former name or former address applicable in the recent reports, indicating continuity in its corporate identity.

Therapeutic focus and product portfolio

In its news releases, Supernus emphasizes a diverse neuroscience portfolio. The company reports that it has approved treatments covering:

• ADHD
• Dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy
• Hypomobility in Parkinson’s disease
• Postpartum depression (PPD)
• Epilepsy
• Migraine
• Cervical dystonia
• Chronic sialorrhea

Supernus also highlights specific commercial products and revenue contributors in its financial results. In its quarterly press releases, the company reports net product sales from Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and a category labeled "Other" that includes MYOBLOC, XADAGO, and Osmolex ER. In addition, Supernus reports collaboration revenue from ZURZUVAE (zuranolone), describing it as collaboration revenue representing a proportionate share of net revenues recorded by Biogen Inc. in the United States.

The company notes that Qelbree and GOCOVRI are key growth products, with Supernus disclosing increases in net sales and prescription volumes for these therapies in its second and third quarter 2025 financial results. Supernus also reports the U.S. commercial launch of ONAPGO, described as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease, and it discusses strong demand and supply constraints for ONAPGO in its filings and press releases.

Acquisition of Sage Therapeutics and collaboration on ZURZUVAE

Supernus has disclosed a significant corporate transaction: the acquisition of Sage Therapeutics, Inc.. In a July 31, 2025 press release and corresponding Form 8-K, the company states that it successfully completed its previously announced acquisition of Sage, with Sage surviving as a wholly owned subsidiary of Supernus. The company describes the acquisition as strengthening its presence in neuropsychiatric conditions through the addition of ZURZUVAE (zuranolone) and a CNS discovery platform, and as further diversifying its revenue base.

In connection with ZURZUVAE, Supernus explains that it receives collaboration revenue equal to 50% of net revenues for ZURZUVAE recorded by Biogen Inc. in the U.S., pursuant to a collaboration agreement originally established between Biogen and Sage. A Biogen press release notes that, following Supernus’s completion of the Sage acquisition in July 2025, Supernus is now the collaboration partner with whom Biogen is working in the U.S. on ZURZUVAE. ZURZUVAE is described in that release as a neuroactive steroid acting as a positive allosteric modulator of GABA-A receptors, indicated for the treatment of postpartum depression in adults.

Research and development pipeline

Supernus reports an active R&D pipeline focused on CNS disorders. In its financial results, the company highlights several product candidates:

• SPN-817 – described as a novel first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy, with a Phase 2b randomized, double-blind, placebo-controlled study ongoing in adults with treatment-resistant focal seizures.
• SPN-820 – described as a novel first-in-class molecule that increases mTORC1-mediated synaptic function for depression. Supernus reports plans for a Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in adults with major depressive disorder, evaluating SPN-820 as an adjunctive treatment to baseline antidepressant therapy.
• SPN-443 – described as a novel stimulant for ADHD/CNS. The company notes completion of a Phase 1 pharmacokinetic study of two oral formulations in healthy adults and indicates that ADHD has been selected as the lead indication in later disclosures.

Across its disclosures, Supernus states that it is developing a broad range of novel CNS product candidates, with new potential treatments for epilepsy, depression, ADHD, and other CNS disorders under investigation.

Business model and revenue sources

Supernus’s public financial reports describe a business model that combines commercialized CNS products with pipeline development. The company reports revenue from:

• Net product sales of its branded CNS therapies, including Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products such as MYOBLOC, XADAGO, and Osmolex ER.
• Royalty, licensing, and other revenues, which the company states include royalties on generic Trokendi XR, Oxtellar XR, other licensed products, and intellectual property.
• Collaboration revenue from ZURZUVAE, representing a share of net revenues recorded by Biogen in the U.S. following the Sage acquisition.

Supernus also discusses non-GAAP financial measures in its earnings releases, such as adjusted operating earnings and total revenues excluding net sales of certain legacy products, to provide additional perspective on its performance as products lose exclusivity and generic competition increases.

Regulatory and reporting status

In multiple Form 8-K filings, Supernus confirms that its common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol SUPN. The company regularly files current reports on Form 8-K to disclose financial results, material corporate transactions such as the Sage acquisition, and other significant events, and it refers investors to its filings under Sections 13 or 15(d) of the Securities Exchange Act of 1934 for additional risk factors and details.

Investor and conference activity

Supernus frequently participates in healthcare and therapeutics conferences hosted by investment banks and other organizations. The company has announced participation in events such as the Bank of America Securities CNS Therapeutics Virtual Conference, the Piper Sandler Annual Healthcare Conference, the Jefferies Global Healthcare Conference, and multiple September investor conferences. In these announcements, Supernus reiterates its focus on CNS diseases and references live audio webcasts of its presentations, indicating an ongoing effort to engage with the investment community.

FAQs about Supernus Pharmaceuticals, Inc. (SUPN)

• What does Supernus Pharmaceuticals, Inc. do?
  Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company reports a diverse neuroscience portfolio with approved treatments for ADHD, Parkinson’s disease-related conditions, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea, along with a pipeline of CNS product candidates.
• On which exchange does SUPN trade?
  According to the company’s Form 8-K filings, Supernus’s common stock is listed on The Nasdaq Stock Market LLC under the trading symbol SUPN.
• What therapeutic areas does Supernus focus on?
  Supernus states that it focuses on central nervous system diseases. Its disclosed portfolio includes therapies for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy, hypomobility in Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
• Which commercial products does Supernus report in its financial results?
  In its quarterly financial releases, Supernus reports net product sales for Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and an "Other" category that includes MYOBLOC, XADAGO, and Osmolex ER. The company also reports collaboration revenue from ZURZUVAE.
• What is the significance of the Sage Therapeutics acquisition?
  Supernus discloses that it completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025. The company describes this transaction as strengthening its presence in neuropsychiatric conditions through the addition of ZURZUVAE and a CNS discovery platform, diversifying its revenue base, and adding a fourth growth product to its portfolio.
• How is Supernus involved with ZURZUVAE (zuranolone)?
  Following the acquisition of Sage Therapeutics, Supernus reports collaboration revenue from ZURZUVAE, representing 50% of net revenues recorded by Biogen Inc. in the U.S. A Biogen press release notes that Supernus is now Biogen’s collaboration partner in the U.S. for ZURZUVAE, an oral treatment indicated for postpartum depression in adults.
• What are some of Supernus’s key growth products?
  In its financial disclosures, Supernus highlights Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE as growth drivers. The company reports strong net sales growth for Qelbree and GOCOVRI, the launch and demand for ONAPGO, and collaboration revenue from ZURZUVAE.
• What pipeline programs does Supernus highlight?
  Supernus describes several CNS-focused product candidates, including SPN-817 for epilepsy, SPN-820 for depression, and SPN-443 as a novel stimulant for ADHD/CNS. The company reports ongoing or planned clinical studies for these candidates in its earnings releases.
• How does Supernus describe its revenue sources?
  Supernus reports revenue from net product sales of its CNS therapies, royalty, licensing and other revenues (including royalties on generic Trokendi XR, Oxtellar XR, other licensed products, and intellectual property), and collaboration revenue from ZURZUVAE.
• Where can investors find official information about Supernus?
  Supernus refers investors to its filings with the U.S. Securities and Exchange Commission, including Forms 8-K and other reports filed under Sections 13 or 15(d) of the Securities Exchange Act of 1934, for detailed financial information, risk factors, and descriptions of its business and transactions.